Global CAR-NK Cell CDMO Service Market Growth (Status and Outlook) 2025-2031

The global CAR-NK Cell CDMO Service market size is predicted to grow from US$ 856 million in 2025 to US$ 1173 million in 2031; it is expected to grow at a CAGR of 5.4% from 2025 to 2031.

CAR-NK cell CDMO service refers to a professional solution that provides a series of outsourcing services, including the design, preparation, production, and quality control of CAR-NK cells, for scientific research institutions, pharmaceutical companies, or medical institutions. CDMO (Contract Development and Manufacturing Organization) services cover multiple aspects, including the construction and optimization of cell lines, the development and validation of production processes, the preparation and testing of preclinical and clinical samples, as well as the release and quality control of final products. By providing professional CDMO services, clients can accelerate the research and development process of CAR-NK cell therapy, reduce development costs, improve research efficiency and quality, and thereby faster push CAR-NK cell therapy from the laboratory to the clinic.

United States market for CAR-NK Cell CDMO Service is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for CAR-NK Cell CDMO Service is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for CAR-NK Cell CDMO Service is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key CAR-NK Cell CDMO Service players cover Hillgene, Porton, Lotuslake Biomedical, Shenzhen Cell Valley, ProBio (GenScript Biotech), etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “CAR-NK Cell CDMO Service Industry Forecast” looks at past sales and reviews total world CAR-NK Cell CDMO Service sales in 2024, providing a comprehensive analysis by region and market sector of projected CAR-NK Cell CDMO Service sales for 2025 through 2031. With CAR-NK Cell CDMO Service sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world CAR-NK Cell CDMO Service industry.

This Insight Report provides a comprehensive analysis of the global CAR-NK Cell CDMO Service landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on CAR-NK Cell CDMO Service portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global CAR-NK Cell CDMO Service market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for CAR-NK Cell CDMO Service and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global CAR-NK Cell CDMO Service.

This report presents a comprehensive overview, market shares, and growth opportunities of CAR-NK Cell CDMO Service market by product type, application, key players and key regions and countries.

Segmentation by Type:
GMP CAR-NK Cell Production
Technology Transfer
Others

Segmentation by Application:
Biopharmaceutical Companies
Research Institutes
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Hillgene
Porton
Lotuslake Biomedical
Shenzhen Cell Valley
ProBio (GenScript Biotech)
Charles River
SinoBiological
Beijing Cygenta Biotech
Promab
Creative-Biogene
Creative-Biolabs
CD Formulaiton

Please note: The report will take approximately 2 business days to prepare and deliver.